Christoffer Clemmensen's Avatar

Christoffer Clemmensen

@clemmensenc.bsky.social

Associate Professor, University of Copenhagen || Co-founder and CSO, Ousia Pharma ApS

453 Followers  |  139 Following  |  8 Posts  |  Joined: 14.11.2024  |  1.6972

Latest posts by clemmensenc.bsky.social on Bluesky

Preview
Shaping the future of cardiometabolic innovation: advances and opportunities - Nature Metabolism Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic interventions to counteract obesity and its associated health risks.

"#Throwback πŸ§ͺ

COMMENT | Shaping the future of cardiometabolic innovation: advances and opportunities

@clemmensenc.bsky.social et al

https://bit.ly/4iIBBvY

06.12.2025 15:26 β€” πŸ‘ 7    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Preview
The science of weight loss – and why your brain is wired to keep you fat The evolutionary science of weight regain unpacked.

"For decades, we’ve been told that weight loss is a matter of willpower: eat less, move more. But modern science has proven this isn’t actually the case."

@clemmensenc.bsky.social and @johansenvbi.bsky.social in @theconversation.com πŸ‘‡

theconversation.com/the-science-...

#obesity #metabolism

10.11.2025 09:03 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0

Congrats Carlos and team, very cool!

26.11.2025 18:56 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
Shaping the future of cardiometabolic innovation: advances and opportunities - Nature Metabolism Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic interventions to counteract obesity and its associated health risks.

"#Throwback πŸ§ͺ

COMMENT | Shaping the future of cardiometabolic innovation: advances and opportunities

@clemmensenc.bsky.social et al

https://bit.ly/494DikH

25.10.2025 14:23 β€” πŸ‘ 4    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
The other end of the weight spectrum: Very thin people Researchers are exploring why some individuals are naturally super-lean and may struggle to gain weight. The causes of such constitutional thinness offer clues to the physiology of weight control.

If our environment promotes obesity, why do some people stay thin? πŸ€”

This new popular scientific article by Ute Eberle in
@knowablemag.bsky.social delves into this question πŸ‘‡ 1/8

@cbmr.science

knowablemagazine.org/content/arti...

13.09.2025 09:54 β€” πŸ‘ 7    πŸ” 5    πŸ’¬ 2    πŸ“Œ 0
Post image Post image

The brain is the master regulator of food intake and energy balance. A brilliant new @cellpress.bsky.social review, including the mechanism of GLP-1 drugs, by @clemmensenc.bsky.social and colleagues, open-access
www.cell.com/cell/fulltex...

08.08.2025 14:38 β€” πŸ‘ 104    πŸ” 22    πŸ’¬ 4    πŸ“Œ 0

Looking for a Postdoc position? (great program with 3-year funding and running costs)

@clemmensenc.bsky.social has a fantastic project in wonderful Copenhagen at the fantastic @cbmr.science research center

Being a program alumni I can can highly recommend the program and the Clemmensen lab :)

01.08.2025 08:18 β€” πŸ‘ 3    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Post image

@cellpress.bsky.social Review 🚨 β€˜Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy’

Lead author: @johansenvbi.bsky.social
Senior author: @clemmensenc.bsky.social

Read it here: www.cell.com/cell/fulltex...

07.08.2025 15:18 β€” πŸ‘ 7    πŸ” 4    πŸ’¬ 0    πŸ“Œ 1
Preview
Shaping the future of cardiometabolic innovation: advances and opportunities - Nature Metabolism Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic...

Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides views on recent breakthroughs, emerging innovations and future needs of therapeutic interventions to counteract obesity and its associated health risks. www.nature.com/articles/s42...

11.07.2025 13:25 β€” πŸ‘ 12    πŸ” 5    πŸ’¬ 1    πŸ“Œ 0
Preview
Shaping the future of cardiometabolic innovation: advances and opportunities Nature Metabolism - Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and...

Unfortunately not up to us to decide on full open access in this case. I hope this link will enable access: rdcu.be/evOFQ Otherwise, I am happy to share a pdf version.

11.07.2025 19:32 β€” πŸ‘ 8    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0
Preview
A hypothalamus–brainstem circuit governs the prioritization of safety over essential needs - Nature Neuroscience Animals need to adapt behavior to balance survival with fulfillment of essential needs. Krauth et al. identify neurons in the lateral hypothalamus that, when activated, prioritize survival over other ...

Honored to share that our paper is out today in Nature Neuroscience:

www.nature.com/articles/s41...

We identify a hypothalamic-brainstem circuit linking internal states to locomotion: These projections drive safety-focused movement over competing behavior.

#Neuroscience #Hypothalamus #Locomotion

28.05.2025 12:19 β€” πŸ‘ 28    πŸ” 8    πŸ’¬ 1    πŸ“Œ 1
Post image

CBMR spinout Ousia Pharma has secured significant seed funding from the Boston-based venture fund Omega Funds to support the preclinical and clinical development of a once-weekly, dual-incretin-NMDA receptor antagonist conjugate.

cbmr.ku.dk/news/2025/cb...

@clemmensenc.bsky.social

#biotech #glp1

06.05.2025 10:03 β€” πŸ‘ 7    πŸ” 1    πŸ’¬ 0    πŸ“Œ 1
Preview
Scarce and unpredictable, yet obesogenic: modeling the impact of food insecurity on adiposity in mice Click on the article title to read more.

Food insecurity drives obesity and adiposity, but how is unclear.
A recent study by @clemmensenc.bsky.social developed a mouse model for this phenomenon lnkd.in/d8pEp2qv
Happy to share a commentary written with @johnspeakman4.bsky.social with our take on that study
doi.org/10.1002/oby....

25.04.2025 10:56 β€” πŸ‘ 7    πŸ” 5    πŸ’¬ 1    πŸ“Œ 1
Preview
Incretin-based therapeutics for the treatment of neurodegenerative diseases Neurodegenerative diseases (NDDs) represent a heterogeneous group of disorders characterized by progressive neuronal loss, which results in significant deficits in memory, cognition, motor skills, and sensory functions. As the prevalence of NDDs rises, there is an urgent unmet need for effective therapies. Current drug development approaches primarily target single pathological features of the disease, which could explain the limited efficacy observed in late-stage clinical trials. Originally developed for the treatment of obesity and diabetes, incretin-based therapies, particularly long-acting GLP-1 receptor (GLP-1R) agonists and GLP-1R–gastric inhibitory polypeptide receptor (GIPR) dual agonists, are emerging as promising treatments for NDDs. Despite limited conclusive preclinical evidence, their pleiotropic ability to reduce neuroinflammation, enhance neuronal energy metabolism and promote synaptic plasticity positions them as potential disease-modifying NDD interventions. In anticipation of results from larger clinical trials, continued advances in next-generation incretin mimetics offer the potential for improved brain access and enhanced neuroprotection, paving the way for incretin-based therapies as a future cornerstone in the management of NDDs. This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s disease.

REVIEW | A Vear, MT Heneka and @clemmensenc.bsky.social
( @cbmr.science , @umasschan.bsky.social )

Review on the potential of incretion-based drugs as treatments of neurodegenerative diseases

29.04.2025 19:08 β€” πŸ‘ 7    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Preview
Incretin-based therapeutics for the treatment of neurodegenerative diseases - Nature Metabolism This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s dise...

Our latest review, led by @anikavear.bsky.social with Michael Heneka, explores the emerging role of incretin-based therapies in neurodegenerative disease treatment www.nature.com/articles/s42...

14.04.2025 09:19 β€” πŸ‘ 11    πŸ” 7    πŸ’¬ 0    πŸ“Œ 0
Preview
Food insecurity promotes adiposity in mice Objective The obesity epidemic, driven by a complex interplay of environmental and biological factors, remains a significant global health challenge. Herein, we investigate the impact of food insecu...

🌟 Exciting News! 🌟
I am thrilled to share that my first paper as the first author, Food insecurity promotes adiposity in mice, is now published in #ObesityJournal #ObesitySociety

doi.org/10.1002/oby....

#Foodinsecurity #Obesity #PhD

1/9πŸ§΅πŸ‘‡

27.03.2025 19:12 β€” πŸ‘ 20    πŸ” 7    πŸ’¬ 2    πŸ“Œ 2
Preview
More strain, more brain: the impact of exercise intensity on neurogenesis Click on the article title to read more.

High-intensity exercise β†’ lactate signaling β†’ neurogenesis? Yes (in some brain areas), but forced treadmill stress might be a potential confounding factor. We unpack this and propose some solutions in our latest JC article in The Journal of Physiology (@jphysiol.bsky.social): doi.org/10.1113/JP28...

12.03.2025 10:27 β€” πŸ‘ 10    πŸ” 4    πŸ’¬ 2    πŸ“Œ 0
Post image

𝐋𝐄𝐀𝐏2: 𝐀 𝐧𝐞𝐰 𝐑𝐨𝐫𝐦𝐨𝐧𝐞 𝐰𝐒𝐭𝐑 𝐛𝐒𝐠 𝐒𝐦𝐩π₯𝐒𝐜𝐚𝐭𝐒𝐨𝐧𝐬 𝐟𝐨𝐫 π¦πžπ­πšπ›π¨π₯𝐒𝐬𝐦?

Research published today in @cp-cellrepmed.bsky.social shows that #insulin and #glucagon play a crucial role in regulating levels of LEAP2 - a newly discovered hormone with promise for treating cardiometabolic disease.

1/

07.03.2025 07:52 β€” πŸ‘ 10    πŸ” 6    πŸ’¬ 1    πŸ“Œ 0
Post image

On #WorldObesityDay, we have contributed a SnapShot to a special Issue on Obesity in @cp-cellmetabolism.bsky.social covering brain actions of the current and emerging weight loss drugs. @jonaspetersen.bsky.social @johansenvbi.bsky.social

Free access link: authors.elsevier.com/a/1kiaA5WXUlaX…

04.03.2025 19:23 β€” πŸ‘ 8    πŸ” 5    πŸ’¬ 0    πŸ“Œ 1
Preview
Pantothenate kinase 4 controls skeletal muscle substrate metabolism - Nature Communications Here, Miranda-Cervantes et al. identified pantothenate kinase 4 (PanK4) as a key regulator of muscle metabolism. Deleting PanK4 impairs fatty acid oxidation and glucose uptake, leading to glucose into...

Curious about muscle metabolism? πŸš΄β€β™‚οΈ We reveal PanK4 as a conserved exercise target in muscle! πŸ’ͺ PanK4 regulates lipid & glucose use likely via acetyl-CoA. We think PanK4 belongs alongside Akt, mTOR, AMPK, Rac1 & more as a key player in muscle energy homeostasis. #Metabolism #MyoBlue

06.01.2025 14:44 β€” πŸ‘ 32    πŸ” 11    πŸ’¬ 2    πŸ“Œ 2

πŸ™

15.12.2024 18:00 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
GLP-1-directed NMDA receptor antagonism for obesity treatment - Nature Unimolecular integration of NMDA receptor antagonism with GLP-1 receptor agonism effectively reverses obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease.

3/3 In parallel, we developed a strategy to target NMDA receptors in appetite-regulating brain regions using peptide-drug conjugates (PDCs). With the ERC grant, we now aim to advance this work by selectively silencing neurons involved in weight regain.
www.nature.com/articles/s41...

04.12.2024 11:08 β€” πŸ‘ 7    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment Scaffolding proteins PICK1 and PSD-95 are genetically linked to obesity and therapeutic targets for sustained weight loss.

2/3 Earlier this year we reported that postsynaptic scaffolding proteins interacting with glutamatergic AMPA and NMDA receptors are potential targets for sustained weight loss
www.science.org/doi/10.1126/...

04.12.2024 11:08 β€” πŸ‘ 7    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0
Preview
ERC grant funds research to support weight loss maintenance Associate Professor Christoffer Clemmensen from the University of Copenhagen has received an ERC Consolidator Grant for a project that aims to develop new therapeutic interventions that will help peop...

1/3 Kicking off my πŸ¦‹ journey with news that my lab has been awarded an ERC Consolidator Grant! Feeling incredibly proud and grateful. The project builds on our long-term focus: homeostatic control of body weight and pharmacological approaches for sustained weight loss. cbmr.ku.dk/news/2024/er...

04.12.2024 11:08 β€” πŸ‘ 36    πŸ” 3    πŸ’¬ 8    πŸ“Œ 1

@clemmensenc is following 20 prominent accounts